Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: End of an era?

Journal of Global Antimicrobial Resistance

Volumn 1, Issue 1, 2013, Pages 23-30

  Bal, A M ^a   Garau, J ^b   Gould, I M ^c   Liao, C H ^d   Mazzei, T ^e   Nimmo, G R ^f   Soriano, A ^g   Stefani, S ^h   Tenover, F C ⁱ  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF FLORENCE   (Italy)

^f Central Queensland Pathology Laboratory   (Australia)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ CEPHEID   (United States)

Author keywords

HVISA; MIC creep; VISA

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; ORITAVANCIN; PANTON VALENTINE LEUKOCIDIN; TEDIZOLID; TELAVANCIN; VANCOMYCIN;

BACTERIAL ENDOCARDITIS; BONE INFECTION; CELLULITIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IN VITRO STUDY; INFECTION COMPLICATION; INFECTIOUS ARTHRITIS; INTENSIVE CARE UNIT; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; OSTEOMYELITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE; WOUND INFECTION;

EID: 84893110180     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2013.01.002     Document Type: Review

References (77)

1. Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select Gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clinic Proceedings 2011;86:1230-43.
2. Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare-associated methicillin- resistant Staphylococcus aureus and its control. Clinical Microbiology and Infection 2010;16:1721-8.
3. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. International Journal of Antimicrobial Agents 2012;39:96-104.
4. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 2010;65:2658- 65.
5. García-Álvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD, et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infectious Diseases 2011;11:595-603.
6. Sharff KA, Monecke S, Slaughter S, Forrest G, Pfeiffer C, Ehricht R, et al. Genotypic resistance testing creates new treatment challenges: two cases of oxacillinsusceptible methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology 2012;50:4151-3.
7. Holmes NE, Johnson PD, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. Journal of Clinical Microbiology 2012;50:2548-52.
8. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clinical Microbiology Reviews 2010;23:99-139.
9. Cafiso V, Bertuccio T, Spina D, Purrello S, Campanile F, Di Pietro C, et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One 2012;7:e29573.
10. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2006;50:1079-82.
11. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrobial Agents and Chemotherapy 2011;55:4012-8.
12. Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR, et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Medical Journal of Australia 2009;191:368-73.
13. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. Journal of Infectious Diseases 2011;204:340-7.
14. Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, et al. Predictors of high vancomycin MIC values among patients with methicillinresistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 2008;62:1138-41.
15. Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC creep'): implications for therapy. F1000 Medicine Reports 2012;4:4.
16. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Archives of Internal Medicine 2006;166:2138-44.
17. Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. Journal of Infection 2010;60:140-5.
18. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycinintermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. Journal of Antimicrobial Chemotherapy 2007;60:788-94.
19. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5- year period. Journal of Clinical Microbiology 2006;44:3883-6.
20. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. Journal of Antimicrobial Chemotherapy 2006;57:506-10.
21. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clinical Infectious Diseases 2006;42(Suppl. 1):S13-24.
22. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. Journal of Clinical Microbiology 2009;47:1640-4.
23. Aló s JI, García-Cañas A, García-Hierro P, Rodríguez-Salvanés F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. Journal of Antimicrobial Chemotherapy 2008;62:773-5.
24. Kehrmann J, Kaase M, Szabados F, Gatermann SG, Buer J, Rath PM, et al. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? European Journal of Clinical Microbiology & Infectious Diseases 2011;30:677-83.
25. Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC 'creep' method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. Journal of Clinical Microbiology 2012;50:318-25.
26. Ludwig F, Edwards B, Lawes T, Gould IM. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology 2012;50:3383-7.
27. van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. Journal of Clinical Microbiology 2011;49:1489-94.
28. Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrobial Agents and Chemotherapy 2009;53:3642-9.
29. Tenover FC. The quest to identify heterogeneously resistant vancomycinintermediate Staphylococcus aureus strains. International Journal of Antimicrobial Agents 2010;36:303-6.
30. Cafiso V, Bertuccio T, Spina D, Purrello S, Blandino G, Stefani S. A novel dhemolysis screening method for detecting heteroresistant vancomycin-inter- mediate Staphylococcus aureus and vancomycin-intermediate S. aureus. Journal of Clinical Microbiology 2012;50:1742-4.
31. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering Jr RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Journal of Clinical Microbiology 2004;42:2398-402.
32. Neoh HM, Hori S, Komatsu M, Oguri T, Takeuchi F, Cui L, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Annals of Clinical Microbiology and Antimicrobials 2007;6:13.
33. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrobial Agents and Chemotherapy 2008;52:3315-20.
34. de Sanctis JT, Swami A, Sawarynski K, Gerasymchuk L, Powell K, Robinson- Dunn B, et al. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia? Diagnostic Molecular Pathology 2011;20:184-8.
35. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 2011;66:2386-92.
36. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clinical Infectious Diseases 2012;54:755-71.
37. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian Journal of Medical Research 2011;134:704-8.
38. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clinical Infectious Diseases 2012;54: 621-9.
39. Sánchez García M, De la Torre MA, Morales G, Peláez B, Tolón MJ, Domingo S, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. Journal of the American Medical Association 2010;303:2260-4.
40. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clinical Infectious Diseases 2010;50:821-5.
41. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrobial Agents and Chemotherapy 2012;56:2342-6.
42. Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrobial Agents and Chemotherapy 2012;56:4403-7.
43. Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200- milligram tedizolid phosphate in healthy adult volunteers. Antimicrobial Agents and Chemotherapy 2012;56:2627-34.
44. Prokocimer PP, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2012;56:4608-13.
45. Rodríguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. Journal of Antimicrobial Chemotherapy 2012;67:167-9.
46. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2010;65(Suppl. 4):iv41-51.
47. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2010;65(Suppl. 4): iv53-65.
48. Low DE, File Jr TM, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 2011;66(Suppl. 3):iii33-44.
49. File Jr TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 2011;66(Suppl. 3):iii19-32.
50. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis 2nd JS. Methicillinresistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. Journal of Antimicrobial Chemotherapy 2012;67:1267-70.
51. File Jr TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clinical Infectious Diseases 2012;55(Suppl. 3):S173-80.
52. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clinical Infectious Diseases 2012;55(Suppl 3):S206-14.
53. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skinstructure infections caused by Gram-positive organisms. Clinical Infectious Diseases 2008;46:1683-93.
54. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Grampositive pathogens. Clinical Infectious Diseases 2011;52:31-40.
55. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, et al. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2012;67:1496-502.
56. Joson J, Grover C, Downer C, Pujar T, Heidari A. Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure. Journal of Antimicrobial Chemotherapy 2011;66: 2186-8.
57. Brinkman MB, Fan K, Shiveley RL, Van Anglen LJ. Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem. Annals of Pharmacotherapy 2012;46:e15.
58. Kaushal R, Hassoun A. Successful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancin. Journal of Antimicrobial Chemotherapy 2012;67:2052-3.
59. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clinical Infectious Diseases 2012;54(Suppl. 3):S214-9.
60. Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin- resistant enterococci and b-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy 2013;68:164-7.
61. Dunbar LM, Milata J, McClure T, Wasilewski MM, SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrobial Agents and Chemotherapy 2011;55:3476-84.
62. Robbel L, Daptomycin Marahiel MA. a bacterial lipopeptide synthesized by a nonribosomal machinery. Journal of Biological Chemistry 2010;285: 27501-08.
63. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 2012;7:e28316.
64. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, et al. b-Lactams increase the antibacterial activity of daptomycin against clinical methicillinresistant Staphylococcus aureus strains and prevent selection of daptomycinresistant derivatives. Antimicrobial Agents and Chemotherapy 2012;56: 6192-200.
65. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrobial Agents and Chemotherapy 2012;56:5046-53.
66. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, et al. Use of antistaphylococcal b-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clinical Infectious Diseases 2011;53: 158-63.
67. Crompton JA, North DS, Yoon M, Steenbergen JN, Lamp KC, Forrest GN. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. Journal of Antimicrobial Chemotherapy 2010;65:1784-91.
68. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, et al. Addition of ceftaroline to daptomycin after the emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrobial Agents and Chemotherapy 2012;56:5296-302.
69. Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ. Daptomycin- nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy 2012;56:5990-3.
70. Moenster RP, Linneman TW, Finnegan PM, McDonald JR. Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Clinical Therapeutics 2012;34:1521-7.
71. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, et al. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011;31: 527-36.
72. Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clinical Infectious Diseases 2011;52(Suppl. 7):S520-6.
73. Schmitz GR, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Annals of Emergency Medicine 2010;56:283-7.
74. Goldberg E, Paul M, Talker O, Samra Z, Raskin M, Hazzan R, et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy 2010;65:1779-83.
75. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2012;56:1619-23.
76. Kavanagh F, Hervey A, Robbins WJ. Antibiotic substances from Basidiomycetes: VIII. Pleurotus multilus (Fr.) Sacc. and Pleurotus passeckerianus Pilat. Proceedings of the National Academy of Sciences of the United States of America 1951;37:570-4.
77. Novak R. Are pleuromutilin antibiotics finally fit for human use? Annals of the New York Academy of Sciences 2011;1241:71-81.